Maravai LifeSciences Holdings, Inc. (MRVI) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Overview
As of June 23, 2026, Maravai LifeSciences Holdings, Inc. (MRVI) reported trailing twelve-month net income of -$105M, reflecting +13.3% year-over-year growth. The company earned $-0.71 per diluted share over the past four quarters, with a net profit margin of -70.4%.
Looking at the long-term picture, MRVI's historical earnings data spans multiple years. The company achieved its highest annual net income of $220M in fiscal 2022.
Maravai LifeSciences Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AZTA (-$178M net income, -9.4% margin), NUVL (-$450M net income), BCAB (-$51M net income, -2980.3% margin), MRVI has room to improve margins relative to the peer group. Compare MRVI vs AZTA →
MRVI Earnings vs Peers
Earnings metrics vs comparable public companies
MRVI Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$131M | +9.7% | -$7M | $-0.91 | -70.4% | -3.6% |
| 2024 | -$145M | -21.7% | -$236M | $-1.05 | -55.9% | -90.9% |
| 2023 | -$119M | -154.1% | -$32M | $-0.90 | -41.2% | -11.0% |
| 2022 | $220M | +21.0% | $574M | $1.67 | 24.9% | 65.0% |
| 2021 | $182M | +136.8% | $555M | $1.56 | 22.8% | 69.4% |
| 2020 | $77M | +1006.1% | $120M | $2.36 | 27.1% | 42.2% |
| 2019 | -$8M | +52.1% | $24M | $-0.05 | -5.9% | 16.8% |
| 2018 | -$18M | - | $16M | $-0.20 | -14.3% | 13.3% |
Download Data
Export MRVI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRVI — Frequently Asked Questions
Quick answers to the most common questions about buying MRVI stock.
What is MRVI earnings per share (EPS)?
MRVI trailing twelve-month (TTM) diluted EPS is $-0.71, reflecting +13.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Maravai LifeSciences Holdings, Inc.'s net income?
Maravai LifeSciences Holdings, Inc. (MRVI) trailing twelve-month net income is $-105M as of 2025. Earnings grew +13.3% year-over-year.
Is MRVI profitable?
MRVI is not currently profitable on a TTM basis, reporting a net loss of $-105M. Net margin is -70.4%. Investors should monitor for a return to profitability.
What is MRVI's earnings growth rate?
MRVI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are MRVI's profit margins?
Maravai LifeSciences Holdings, Inc. net profit margin is -70.4%, operating margin is -3.6%, and gross margin is +18.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -27.5%.
Is MRVI growing earnings?
MRVI is growing earnings steadily. YoY EPS growth of +13.3% is consistent with the 5-year CAGR of N/A. TTM net income is $-105M.
What was MRVI's best earnings year?
Maravai LifeSciences Holdings, Inc.'s highest annual net income on record is $220M, achieved in fiscal year 2022. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were MRVI's earnings last quarter?
MRVI's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.